Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia

Summary

The aim of this study is to determine if suvorexant can help treat the severity of insomnia and improve metabolic health in midlife women who had both insomnia and indicators of metabolic syndrome.

Timeline

Start

2023-01-06

Primary completion

2025-10-24

Completion

2025-10-24

Outcome

Met primary endpoint

registry MEAN Suvorexant: Change from Baseline at 4 weeks: -5.8 (Standard Deviation 4.9) units on a scale NCT05593653 ↗

registry analysis (superiority test); Suvorexant vs Placebo; p = 0.04; Mixed Models Analysis NCT05593653 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Suvorexant	Small molecule	20 mg	Oral

Indications